RecruitingPHASE1, PHASE2INTERVENTIONAL

A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours

This study is looking at a new experimental drug called ATTR-01 for adults with specific types of solid cancers. The drug is made from a common cold virus that has been changed so it only infects and grows in cancer cells. It then delivers a treatment that helps your body's own immune system find and attack the cancer. This is the first time ATTR-01 is being tested in people. The first part of the study will help doctors find the best dose to use. If successful, later parts of the study will explore how well ATTR-01 can treat cancer.

At a glance

Status

Recruiting

Phase

PHASE1, PHASE2

Sponsor

Accession Therapeutics Limited

Enrolment target

Start

21 Mar 2025

Estimated completion

31 Dec 2034

Solid Tumor, Adult

What is this study about?

This clinical trial is investigating a new drug called ATTR-01 for people who have certain types of solid tumours. Solid tumours are a group of abnormal cells that grow into a mass. Researchers are always looking for new and better ways to treat cancer, and ATTR-01 is one of these new approaches.

Here's how ATTR-01 works: it's based on a common cold virus, but it's been specially altered in the laboratory. This altered virus is designed to only infect and multiply within cancer cells, leaving healthy cells alone. Once inside the cancer cells, the virus delivers a special treatment that helps to boost your body's own immune system. The idea is that your immune system, which is your body's natural defense, will then become stronger and more effective at recognising and destroying the cancer cells.

This study is in its early stages (Phase 1 and Phase 2), meaning it's one of the first times this drug is being given to people. The main goal of the first part of the study is to find a safe and effective dose of ATTR-01. If the drug shows promise, more studies will be done to understand how well it works against cancer.

Key takeaways

ATTR-01 is a new drug using a modified virus to fight cancer.
It aims to boost your own immune system to attack cancer cells.
This is an early-stage study to find a safe dose and see initial effects.
It's for adults with specific solid tumours who've tried other treatments.
Taking part means regular check-ups and following safety guidelines.

Who may be eligible?

This study is open to adults aged 18 and over who have specific types of solid tumours. Importantly, these tumours must have a particular feature (called αvβ6 integrin receptor expression) that ATTR-01 is designed to target. You would need to have already tried standard treatments for your cancer, but they either didn't work well enough or caused side effects you couldn't tolerate.

To be considered for the study, you'll need to be generally well enough to take part and have a good expected lifespan of more than three months. Your cancer must also be measurable so doctors can track any changes. You should not have serious lung conditions caused by scarring (fibrosis) or a history of severe reactions to certain other immune-boosting cancer treatments.

Patients will need to be willing to follow hygiene instructions to prevent any spread of the virus and protect others, especially those who might be vulnerable. It's also important that your organs are working properly, and you're able to follow all wash-out periods for previous treatments and specific contraception requirements for new drug therapies.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Do you have a solid tumour that your doctor thinks might fit this study?
Have you already tried standard treatments for your cancer, or found them too difficult to tolerate?
Are you generally well enough to participate in a study?
Are you willing to follow specific hygiene instructions for safety?

Answer every question to see your result.

What does participation involve?

Taking part in this study would involve receiving the experimental drug ATTR-01. Since this is an early-stage study, you would have several clinic visits to monitor your health, receive the treatment, and have tests such as blood samples and imaging scans. You will also need to have small samples of your tumour taken before and after treatment to see how the drug is affecting it. The exact number of visits and tests would be explained in detail by the study team. You would also be asked to follow specific hygiene measures. The total duration of your participation would depend on how your treatment progresses and the study's follow-up plan.

Potential risks and benefits

As with any clinical trial, there are potential benefits and risks. The potential benefit is that ATTR-01 might help to treat your cancer, especially if standard treatments haven't been effective. However, because this is an experimental drug, there's also the chance it may not work for you, or it could cause side effects that are currently unknown. The study team will explain all known and potential risks in detail. Remember, your participation is voluntary, and you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (8)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

START Barcelona
Verified postcode
Barcelona, Spain· Recruiting
Start Fjd
Verified postcode
Madrid, Spain· Recruiting
Start Hm Ciocc
Verified postcode
Madrid, Spain· Recruiting
General Hospital San Pedro - START
Verified postcode
Rioja, Spain· Not yet recruiting
Beatson West of Scotland Cancer Centre
Verified postcode
Glasgow, United Kingdom· Recruiting
Velindre Cancer Centre
Verified postcode
Cardiff, United Kingdom· Recruiting
, St James' University Hospital
Verified postcode
Leeds, United Kingdom· Recruiting
Churchill Hospital
Verified postcode
Oxford, United Kingdom· Recruiting

Common questions

What is ATTR-01?

ATTR-01 is a new experimental drug that uses a modified common cold virus to target and treat certain cancer cells.

Will ATTR-01 cure my cancer?

It's too early to say if ATTR-01 will cure cancer. This study is designed to see if it's safe and if it shows promise as a new treatment.

What kind of cancers is this study for?

This study is for adults with specific types of solid tumours that have a particular feature the drug is designed to target.

Will I get the actual drug, or a dummy treatment?

In this specific study, all participants will receive the experimental drug ATTR-01, as it's testing safety and dosage.

Can I stop participating in the study at any time?

Yes, you can choose to leave the study at any point, and it won't affect your future medical care.

How to find out more

Hardev Pandha, Professor

clinicaloperations@accessiontherapeutics.com +44 1865-950220 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.